Effects of suplatast tosilate on airway inflammation and interleukin-5 in asthmatic rats.
- Author:
Dan LIU
1
;
Yun LI
;
Li-Li ZHONG
;
Yu-Pin TAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Arylsulfonates; therapeutic use; Asthma; drug therapy; immunology; pathology; Eosinophils; drug effects; Interleukin-5; analysis; antagonists & inhibitors; genetics; Lung; metabolism; pathology; Male; Rats; Rats, Sprague-Dawley; Sulfonium Compounds; therapeutic use
- From: Chinese Journal of Contemporary Pediatrics 2014;16(7):759-763
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of suplatast tosilate (IPD) on the airway inflammation and expression of interleukin-5 in asthmatic rats.
METHODSFifty adult male Sprague-Dawley rats (4-week- old) were randomly assigned to five groups: placebo control, untreated asthma, budesonide(BUD)-treated asthma , early or late IPD intervention group (n=10 rats each). Asthmatic mode was prepared by ovalbumin sensitizion and challenge. Inflammatory cells and the percentage of EOS were detected in bronchoalveolar lavage fluid (BALF). The lung tissues were removed to detect the lung histomorphology. Gene expression of IL-5 was measured by reverse transcription-polymerase chain reaction (RT-PCR). Levels of interleukin 5 (IL-5) in BALF were measured using ELISA.
RESULTSThe inflammatory cells and the percentage of EOS in BALF, IL-5 levels in BALF and IL-5 mRNA expression in the lung tissues were obviously higher in the untreated asthma group than the control group (P<0.05), while the parameters in the IPD or BUD-treated asthma groups were significantly lower than the untreated asthma group (P<0.05).
CONCLUSIONSIPD treatment can alleviate airway inflammation in asthmatic rats, possibly through inhibiting IL-5 mRNA transcripts.
